RATIONALE: Perphenazine, a classical antipsychotic drug, has the potential to induce extrapyramidal side effects (EPS). Dopaminergic and serotonergic pathways are involved in the therapeutic and adverse effects of the drug. OBJECTIVES: To evaluate the impact of polymorphisms in the dopamine D(2) and D(3) and serotonin 2A and 2C receptor genes (DRD2, DRD3, HTR2A, and HTR2C) on short-term effects of perphenazine monotherapy in schizophrenic patients. MATERIALS AND METHODS: Forty-seven Estonian inpatients were evaluated before and after 4-6 weeks of treatment by Simpson-Angus rating scale, Barnes scale, and Positive and Negative Symptom Scale. Genotyping was performed for common DRD2, DRD3, HTR2A, and HTR2C gene polymorphisms, previously reported to influence receptor expression and/or function. RESULTS: Most of the patients (n = 37) responded to the treatment and no significant association was observed between the polymorphisms and antipsychotic response. The 102C allele of HTR2A and the -697C and 23Ser alleles of HTR2C were more frequent among patients with EPS (n = 25) compared to patients without EPS (n = 22) (p = 0.02, 0.01, and 0.02, respectively). The difference between patients with and without EPS in variant allele frequencies remained significant after multiple model analyses including age, gender, and duration of antipsychotic treatment as covariants. There was no significant association between EPS occurrence and polymorphisms in the DRD2 and DRD3 genes. CONCLUSIONS: An association was observed between polymorphisms in HTR2A and HTR2C genes and occurrence of acute EPS in schizophrenic patients treated with perphenazine monotherapy. Larger study populations are needed to confirm our findings.
RATIONALE: Perphenazine, a classical antipsychotic drug, has the potential to induce extrapyramidal side effects (EPS). Dopaminergic and serotonergic pathways are involved in the therapeutic and adverse effects of the drug. OBJECTIVES: To evaluate the impact of polymorphisms in the dopamine D(2) and D(3) and serotonin 2A and 2C receptor genes (DRD2, DRD3, HTR2A, and HTR2C) on short-term effects of perphenazine monotherapy in schizophrenicpatients. MATERIALS AND METHODS: Forty-seven Estonian inpatients were evaluated before and after 4-6 weeks of treatment by Simpson-Angus rating scale, Barnes scale, and Positive and Negative Symptom Scale. Genotyping was performed for common DRD2, DRD3, HTR2A, and HTR2C gene polymorphisms, previously reported to influence receptor expression and/or function. RESULTS: Most of the patients (n = 37) responded to the treatment and no significant association was observed between the polymorphisms and antipsychotic response. The 102C allele of HTR2A and the -697C and 23Ser alleles of HTR2C were more frequent among patients with EPS (n = 25) compared to patients without EPS (n = 22) (p = 0.02, 0.01, and 0.02, respectively). The difference between patients with and without EPS in variant allele frequencies remained significant after multiple model analyses including age, gender, and duration of antipsychotic treatment as covariants. There was no significant association between EPS occurrence and polymorphisms in the DRD2 and DRD3 genes. CONCLUSIONS: An association was observed between polymorphisms in HTR2A and HTR2C genes and occurrence of acute EPS in schizophrenicpatients treated with perphenazine monotherapy. Larger study populations are needed to confirm our findings.
Authors: E G Jönsson; M M Nöthen; F Grünhage; L Farde; Y Nakashima; P Propping; G C Sedvall Journal: Mol Psychiatry Date: 1999-05 Impact factor: 15.992
Authors: R H Segman; U Heresco-Levy; B Finkel; R Inbar; T Neeman; M Schlafman; A Dorevitch; A Yakir; A Lerner; T Goltser; A Shelevoy; B Lerer Journal: Psychopharmacology (Berl) Date: 2000-11 Impact factor: 4.530
Authors: Bernard Lerer; Ronnen H Segman; Heiner Fangerau; Ann K Daly; Vincenzo S Basile; Roberto Cavallaro; Harald N Aschauer; Robin G McCreadie; Stephanie Ohlraun; Nicol Ferrier; Mario Masellis; Massimiliano Verga; Joachim Scharfetter; Marcella Rietschel; Roger Lovlie; Uriel Heresco Levy; Herbert Y Meltzer; James L Kennedy; Vidar M Steen; Fabio Macciardi Journal: Neuropsychopharmacology Date: 2002-07 Impact factor: 7.853
Authors: G Spurlock; A Heils; P Holmans; J Williams; U M D'Souza; A Cardno; K C Murphy; L Jones; P R Buckland; P McGuffin; K P Lesch; M J Owen Journal: Mol Psychiatry Date: 1998-01 Impact factor: 15.992
Authors: Jeroen P Koning; Jelle Vehof; Huibert Burger; Bob Wilffert; Asmar Al Hadithy; Behrooz Alizadeh; Peter N van Harten; Harold Snieder Journal: Psychopharmacology (Berl) Date: 2011-07-13 Impact factor: 4.530
Authors: S Mas; P Gassó; A Lafuente; M Bioque; A Lobo; A Gonzàlez-Pinto; M S Olmeda; I Corripio; A Llerena; B Cabrera; J Saiz-Ruiz; M Bernardo Journal: Pharmacogenomics J Date: 2016-06-07 Impact factor: 3.550
Authors: B Almoguera; R Riveiro-Alvarez; J Lopez-Castroman; P Dorado; C Vaquero-Lorenzo; J Fernandez-Piqueras; A Llerena; F Abad-Santos; E Baca-García; R Dal-Ré; C Ayuso Journal: Pharmacogenomics J Date: 2012-01-03 Impact factor: 3.550